Related Experiment Videos
Recovery after stem-cell transplantation for hematologic diseases
S J Lee1, D Fairclough, S K Parsons
1Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. stephanie_lee@dfci.harvard.edu
Summary
Recovery after stem-cell transplantation (SCT) shows encouraging trends, with most patients experiencing fewer bothersome symptoms and continued improvement through the first year post-transplant. These findings aid in setting realistic expectations for patients undergoing SCT.
Area of Science:
- Hematology
- Oncology
- Transplant Medicine
Background:
- Stem-cell transplantation (SCT) is increasingly utilized for hematologic malignancies and other disorders.
- Limited quantitative data exists regarding patient recovery and quality of life post-SCT, hindering effective patient counseling.
Purpose of the Study:
- To establish reasonable expectations for recovery and symptom burden following autologous and allogeneic SCT.
- To assess recovery using objective health status measures, quality of life indicators, and specific symptom quantification.
Main Methods:
- A prospective, longitudinal questionnaire study was conducted.
- Participants included recipients of autologous and allogeneic SCT at a tertiary-care transplant center.
- Response rates among survivors at 6, 12, and 24 months ranged from 85% to 88%.
Main Results:
- While autologous SCT recipients initially showed better survival and recovery, differences largely equalized by 12 months post-transplant.
- Less than 24% of patients reported bothersome symptoms, excluding fatigue, financial, and sexual difficulties.
- Continued recovery and a low level of bothersome symptoms were observed through the first year.
Conclusions:
- Findings provide valuable insights for counseling patients considering SCT, outlining realistic recovery expectations.
- The study highlights encouraging trends in symptom reduction and overall recovery within the first year after SCT.